As previously reported, William Blair downgraded NeoGenomics (NEO) to Market Perform from Outperform after the company reported Q2 results and cut ...

William Blair downgraded NeoGenomics (NEO) to Market Perform from Outperform. Published first on TheFly – the ultimate source for real-time, ...

Exelixis Q2 revenue missed estimates, but strong Cabometyx sales lifted earnings. STELLAR trial delays and strategy shifts ...

Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for ...

Incyte posts strong Q2 results driven by Jakafi and Opzelura growth, lifts 2025 guidance despite challenges in future product development.

CoStar’s second quarter saw solid execution, with revenue and non-GAAP earnings both surpassing Wall Street expectations, ...

Global Industrial Company posts record Q2 2025 performance with 3.2% revenue growth, margin gains, and strategic shifts toward customer-centricity ...

Manhattan Associates delivered a positive Q2, with the market responding strongly to the company's better-than-expected results. Management attributed the quarter’s outperformance to robust growth in ...

Sarepta Therapeutics shares jumped over 36% on Tuesday after the company said it had received FDA approval to restart ...

Executives at the laboratory companies said they expect the effects on testing services from the Republicans’ tax and ...

Compared to the previous quarter, both analysts and management exhibited increased caution and a more defensive posture, particularly around guidance credibility and nonclinical revenue challenges.

After leaving Wall Street's expectations in the dust, the San Francisco-based fintech dialed up its outlook for the rest of 2025. And as regulators warm to crypto, SoFi sees opportunities for years to ...